3SBio (OTCMKTS:TRSBF) (OTCMKTS: TRSBF) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of protein-based therapeutics and chemical drugs. Established in 1999 and headquartered in Shenyang, Liaoning Province, the company has built an integrated platform that encompasses in-house R&D capabilities, clinical development, commercial production and a nationwide sales network.
The company’s product portfolio features a range of hematopoietic growth factors such as recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human erythropoietin (rhEPO), insulin and insulin analogs, hemostasis agents and monoclonal antibodies. Several of these products have received regulatory approval in China, where 3SBio holds market share in its core therapeutic areas. In addition to its approved drugs, the company maintains an active pipeline of biologics and small-molecule candidates targeting oncology, immunology and metabolic disorders.
3SBio operates multiple R&D centers and cGMP-compliant manufacturing facilities across China, supporting both commercial scale production and clinical supply. The company’s domestic sales force and distribution network extend coverage to hospitals and specialty clinics nationwide. While its primary market remains mainland China, 3SBio has entered into strategic collaborations and licensing arrangements with multinational partners to explore overseas markets and co-development opportunities.
Management brings together experienced professionals in biotechnology and pharmaceutical development. Over the years, 3SBio has leveraged strategic partnerships, internal innovation and contract manufacturing expertise to establish itself as one of China’s leading biopharmaceutical firms serving patients with targeted therapies and essential biologics.
